Global Antihypertensive Drugs Market Surges to US$30.2 Billion in 2021: A Comprehensive Outlook

The global Antihypertensive Drugs Market is witnessing remarkable growth, reaching a valuation of US$ 30.2 billion in 2021 and projected to expand at a CAGR of 3.0% from 2022 to 2031. Analysts anticipate the market to exceed US$ 40 billion by the end of 2031. This growth is attributed to various factors such as the surge in the launch of new drugs, collaborative initiatives, and the establishment of research and development (R&D) centers. Notable collaborations, like the one between Daiichi Sankyo and the University of California San Francisco's Institute for Neurodegenerative Diseases, underscore the industry's commitment to advancing drug development.

The rise in disposable income, coupled with advancements in disease-modifying therapies, is expected to propel the global antihypertensive drugs market. Furthermore, the significant growth in telemedicine and e-Health apps is creating long-term revenue opportunities for companies in this sector. Despite the availability of modern and effective antihypertensive drugs, there remains a reasonably high unmet demand, indicating the need for more effective products.

Download Sample PDF copy of the Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=7718

Overview of Antihypertensive Medications
Antihypertensive medications play a crucial role in treating high blood pressure, a preventable risk factor for atherosclerotic disease and ischemic heart disease. The market offers various types of antihypertensive drugs, each addressing blood pressure in different ways. Some remove excess fluid and salt from the body, while others relax and widen blood vessels or slow the heart rate. Combination therapy, involving the addition of another class of blood pressure medication to enhance effectiveness, is common for achieving treatment goals.

Trends and Opportunities
The market is witnessing trends in antihypertensive medication in stroke survivors, providing valuable insights into gaps in secondary prevention. Healthcare companies are intensifying research and development in genomics and resistant hypertension treatment to gain a competitive edge. The launch of new disease-modifying therapies, innovative drug formulations, and promising products in the pipeline are expected to drive demand in the coming years.

Launch of New Disease-modifying Therapies
Innovative antihypertensive drugs and therapies targeting disease progression are expected to have favorable outcomes. The global market is poised for a transformation with the launch of new therapies, including angiotensin II receptor blockers (ARBs), angiotensin converting enzyme (ACE) inhibitors, and calcium channel blockers (CCB). Notably, physicians are increasingly prescribing ACE and CHF inhibitors over diuretics and beta-blockers. Launching innovative drug molecules with disease-modifying properties, improved efficacy, and safety is anticipated to be a key driver of the market's growth.

Promising Products in Pipeline
The pipeline for antihypertensive drugs includes treatments with disease-modifying properties, better safety profiles, and increased effectiveness. Notable drugs in development include Bayer's candesartan cilexetil/nifedipine (phase III), Boryung Pharmaceuticals' fimasartan/amlodipine (phase III), and Takeda Pharmaceuticals' diuretic azilsartan/amlodipine/hydrochlorothiazide (phase III). These products aim to address unmet needs and provide more efficient and safer alternatives for hypertension management.

Any Query? Ask to Expert: https://www.transparencymarketresearch.com/sample/sample.php?flag=ASK&rep_id=7718

Stable Revenue Streams through Angiotensin Receptor Blockers
The market's therapy type classification includes diuretics, ACE inhibitors, angiotensin receptor blockers, beta-blockers, vasodilators, calcium channel blockers, renin inhibitors, alpha-blockers, and others. Among these, the angiotensin receptor blockers segment is projected to dominate, offering stable revenue streams. ARBs function similarly to ACE inhibitors but operate on a different mechanism, contributing to their widespread adoption in the treatment of hypertension.

Primary Hypertension Management Driving Demand
The global market is categorized based on hypertension types into primary hypertension and secondary hypertension. Primary hypertension is expected to dominate, growing at a high CAGR from 2021 to 2031. The prevalence of hypertension as a global health concern, driven by factors such as high salt intake, is contributing to the demand for antihypertensive drugs for primary hypertension management.

Combination Therapy on the Rise
In terms of medication, the market is segmented into monotherapy, combination therapy, and fixed-dose combinations. The combination therapy segment is projected to dominate, driven by the rise in the geriatric population with comorbid conditions such as congenital heart disease. Manufacturers are increasing the production of combination antihypertensive drugs to meet the specific needs of elderly patients with multiple health issues.

Hospital Pharmacies Leading in Distribution
Distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and others. The hospital pharmacies segment dominated the global market in 2021, offering a wide range of medicines, including specialized and investigational medications. The availability of hypertension management devices in hospital pharmacies is expanding, contributing to their leading position in the market.

Regional Outlook
North America led the global antihypertensive drugs market in 2021 and is projected to maintain its dominance, growing at a high CAGR from 2022 to 2031. Factors such as high adoption of antihypertensive drugs in the U.S., increased approvals for new drugs by the U.S. FDA, and a rising percentage of people suffering from cardiovascular diseases in the U.S. and Canada contribute to North America's significant market share. The Asia Pacific region is expected to experience substantial growth, driven by a large patient pool, an increase in the incidence of heart diseases, an aging population, and high demand for drug exports to Europe and North America.

Analysis of Key Players:
Pfizer, Inc., Sanofi S.A, Novartis AG, Boehringer Ingelheim GmbH, Actelion Ltd., F. Hoffmann-La Roche Ltd., Bayer AG, Daiichi Sankyo Company, Limited, and Takeda Pharmaceutical Company Limited

Buy this Premium Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=7718<ype=S

Explore More Trending Report by Transparency Market Research:

Laboratory Automation Systems Market: https://www.globenewswire.com/en/news-release/2023/09/01/2735889/32656/en/Global-Laboratory-Automation-Systems-Market-Predicted-to-Reach-USD-11-0-billion-by-2031-Registering-at-a-CAGR-of-5-8-Exclusive-Report-by-Transparency-Market-Research.html

EClinical Solutions Market: https://www.globenewswire.com/en/news-release/2023/09/11/2740697/32656/en/EClinical-Solutions-Market-is-Anticipated-to-Reach-a-Valuation-of-US-29-9-Billion-by-2031-Projecting-an-Impressive-13-6-CAGR-from-2023-to-2031-Transparency-Market-Research-Inc.html

0About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:
Nikhil Sawlani
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

This release was published on openPR.